The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab Use Increasing in Treatment of Pediatric Vasculitis

Rituximab Use Increasing in Treatment of Pediatric Vasculitis

December 20, 2017 • By Catherine Kolonko

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Because the disease is rarer in children, pediatricians who treat these young patients with AAV may go months or longer before encountering another case. “Some places may see one of these kids every few years,” says Dr. James.

You Might Also Like
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
Explore This Issue
December 2017

That often means a physician with experience treating a child with one effective medicine may prove reluctant to transition to a new one (e.g., rituximab) when treating the next child. Studying AAV regimens used for pediatric patients across the nation brings an understanding to actual practices and how they vary, says Dr. James, noting that different ways exist to treat diseases.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Study

In this study, researchers reviewed data from 2004–2014 involving pediatric patients hospitalized with AAV. Using an administrative and billing database from 47 tertiary care pediatric hospitals throughout the country, the researchers examined factors surrounding the initial hospitalization and initial treatments for children later discharged with a diagnosis code of AAV.

Of 523 pediatric patients screened, 393 met the study criteria, which targeted newly diagnosed patients with active disease and those with a new relapse of disease. The average age of study participants was approximately 14 years old, and slightly more girls (61%) than boys were included. The average time in the hospital was nine days for first admissions, and about twice that for patients needing dialysis and/or mechanical ventilation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“These are patients who haven’t been admitted in six months,” Dr. James says about those included in her study. “Either they are [newly diagnosed], or they’re [experiencing disease] flares.”

Doctors generally give induction treatments to both newly diagnosed patients and those who experience a flare. Thus, the study targeted patients who had received similar therapy.

“You get … an induction treatment,” says Dr. James, explaining typical therapy for pediatric patients in the study. “Things are quiet. You get on a maintenance medication. Maybe you are still on the maintenance or maybe you’ve come off it, and you have a flare of disease and you go back to induction.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers tracked how many patients received cyclophosphamide and rituximab and whether use of the drugs increased or decreased over the years. It also considered other treatment factors, such as the need for dialysis and mechanical ventilation, and use of plasma exchange, an additional option often used for the sickest patients.

“There was an increasing trend in the use of rituximab over time during the study period (P<0.05) and a decreasing trend in the use of cyclophosphamide (P<0.05),” the article states. “Treatment use varied significantly between hospitals, especially for plasma exchange.”

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: AAV, AC&R, American College of Rheumatology, antibody-associated vasculitis, Arthritis Care & Research, Children, Clinical, cyclophosphamide, Diagnosis, drug, outcome, patient care, Pediatric, Research, rheumatologist, rheumatology, rituximab, study, therapy, treament, VasculitisIssue: December 2017

You Might Also Like:
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
  • Latest Research on Cutaneous Vasculitis Diagnosis, Treatment

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)